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(Shortman and Liu, 2002; Vremec et al., 2000). CD8Wayne W. Hancock,2,5 Jorge H. Caamano,6
DCs are localized mainly in the T cell areas, whereasChristopher A. Hunter,4 Phillip Scott,4
the majority of CD8 DCs are found in the marginalLaurence A. Turka,3 and Yongwon Choi1,2,*
zones but can be induced to migrate into the T cell areas1Abramson Family Cancer Research Institute
upon activation (Banchereau et al., 2000). Although2 Department of Pathology and Laboratory Medicine
characterization of the different splenic DC subsets has3 Department of Medicine
been limited and remains unclear, it has been suggestedUniversity of Pennsylvania School of Medicine
that they determine the distinct nature of T cell re-4 Department of Pathobiology
sponses (Th1 versus Th2; T cell activation versus toler-University of Pennsylvania School
ance) (Legge et al., 2002; Moser and Murphy, 2000).of Veterinary Medicine
Immature DCs in the periphery uptake antigens effi-5 The Children’s Hospital of Philadelphia
ciently but express low levels of MHC and costimulatoryPhiladelphia, Pennsylvania 19104
molecules and thus possess a low level of T cell stimula-6 Medical Research Council Center for Immune
tory capacity. Upon maturation DCs greatly augment theirRegulation
ability to stimulate naive T cells by dramatically upregu-University of Birmingham
lating surface expression of antigen/MHC complexesBirmingham B15 2TT
and various costimulatory molecules. DC maturationEngland
can be triggered by a response to microbial components
(e.g., lipopolysaccharide [LPS], double-stranded RNA,
or CpG-DNA) or inflammatory cytokines such as CD40LSummary
(Banchereau et al., 2000; Banchereau and Steinman,
1998). These stimuli also activate DCs to secrete cytokinesIL-1 receptor (IL-1R)/Toll-like receptor (TLR) family
including IL-12, which is critical for the differentiationand TNF receptor (TNFR) superfamily members are
of T cells into Th1 type effector cells (Trinchieri, 2003).critical for regulating multiple aspects of dendritic cell
Recently, key regulatory factors for DC maturation(DC) biology. Several signaling pathways associated
and activation have begun to be identified. DCs canwith each family utilize the adapter molecule, TRAF6,
recognize microbial components using various patternbut its role in DCs is unclear. By examining TRAF6-
recognition receptors called Toll-like receptors (TLRs)deficient mice and bone marrow (BM) chimeras recon-
(Janeway and Medzhitov, 2002). Different TLRs ex-stituted with TRAF6-deficient fetal liver cells, we show
pressed on DCs can discriminate distinct pathogen-that proper DC maturation requires TRAF6. In re-
associated molecular patterns (PAMPs) and initiate sig-sponse to either microbial components or CD40L,
naling pathways to induce DC maturation and activationTRAF6-deficient DCs fail to upregulate surface ex-
(Janeway and Medzhitov, 2002). For example, CpG-DNApression of MHCII and B7.2, or produce inflammatory
utilizes TLR9 to induce DC maturation, cytokine produc-cytokines. Moreover, LPS-treated TRAF6-deficient
tion, and T cell stimulatory activity, while LPS stimulatesDCs do not exhibit an enhanced capacity to stimulate
DCs through TLR4 (Hemmi et al., 2000; Kaisho and Akira,naive T cells. Interestingly, a major population of
2001; Kaisho et al., 2001).splenic DCs, the CD4CD8 subset, is nearly absent
Upon recognition of their cognate ligands, TLRs re-
in both TRAF6-deficient mice and BM chimeras. To-
cruit the cytoplasmic adaptor protein, MyD88, leading
gether these results indicate that TRAF6 regulates the to the activation of various kinases (e.g., IKK, MAPK)
critical processes required for maturation, activation, and transcription factors (e.g., NF-B) (Medzhitov et al.,
and development of DCs, the primary cellular bridge 1998; Muzio et al., 1998). DCs from MyD88-deficient
between innate and adaptive immunity. mice fail to elaborate cytokines in response to CpG-
DNA, LPS, and other microbial components, implicating
Introduction MyD88 in the signaling pathways of most, if not all, TLRs.
However, further examination of DC maturation has re-
Dendritic cells (DCs) specialize in capturing, processing, vealed apparently distinct classes of TLRs, as CpG-DNA
transporting, and presenting antigens to T cells (Ban- fails to upregulate surface expression of MHCII and
chereau et al., 2000; Banchereau and Steinman, 1998). other costimulatory molecules on MyD88-deficient DCs,
DCs initiate primary T cell responses by presenting anti- whereas, surprisingly, LPS induces normal phenotypic
genic peptides on MHC molecules and providing co- maturation (Kaisho and Akira, 2001; Kaisho et al., 2001).
stimulatory signals that are essential for optimal T cell This finding suggested the existence of a MyD88-inde-
responses. DCs are heterogeneous in phenotype, local- pendent signaling pathway(s) for TLR4-mediated induc-
ization, and function. To date, the following three DC tion of DC maturation. Therefore, two distinct intracellu-
subsets have been described in the mouse spleen based lar signaling pathways appear to regulate DC maturation
by different TLRs: one class (e.g., TLR9) is strictly depen-
dent on MyD88 while the other (e.g., TLR4) can induce*Correspondence: ychoi3@mail.med.upenn.edu
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Figure 1. Phenotypic DC Maturation and Cytokine Production Are Impaired in TRAF6-Deficient DCs
(A) Phenotypic maturation of TRAF6/ DCs is impaired in vitro. DCs were generated from the spleens of TRAF6/ mice or control littermates
in vitro. DCs were left untreated (filled histogram) or stimulated as indicated (open histogram), and surface I-Ab and B7.2 levels were analyzed
by flow cytometry. Results are representative of at least three independent experiments.
(B) LPS- and CD40-induced DC maturation is impaired in TRAF6/ mice in vivo. (Top) LPS or PBS was injected into TRAF6/ and control
mice. Six hours later, I-Ab and CD86 expression levels on CD11chigh DC populations were compared between PBS-injected (filled histogram)
and LPS-injected (open histogram) mice. Results are typical of three independent experiments with similar results. (Bottom) Anti-CD40 Ab
was injected i.p., and DCs were analyzed 27 hr later. I-Ab and CD86 expression levels on CD8 CD11chigh DC populations were compared
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DC maturation in the absence of MyD88. Whether components and CD40L. In addition, we show that
TRAF6 is required for induction of cytokine productionMyD88-dependent and -independent signaling path-
ways converge during TLR-induced DC maturation re- by DCs and for acquisition of enhanced T cell stimulatory
capacity. Unexpectedly, we also found that TRAF6 defi-mains unknown.
Some of the transcription factors activated by TLR- ciency results in a developmental defect in the genera-
tion of the splenic CD4 DC subset. On the basis of theMyD88 have also been implicated in the regulation of
DC function (Ouaaz et al., 2002). It has been reported results presented here, we propose a pivotal function
of TRAF6 in the regulation of DC maturation and thethat p50/cRel double knockout DCs fail to produce IL-
12 in responses to LPS and other microbial components. development of DC subsets.
Therefore, it is likely that the MyD88-NF-B (particularly
the p50 and cRel subunits) signaling pathway is essen- Results
tial for inflammatory cytokine production by DCs stimu-
lated through most, if not all, TLRs. However, p50/cRel Functional Disruption of TRAF6 in Mice
To disrupt the functional TRAF6 protein in vivo, we em-double knockout DCs still phenotypically mature in re-
sponse to LPS (Ouaaz et al., 2002), indicating that other ployed a knockin vector that enabled us to delete a
floxed TRAF6 exon 7 encoding the last zinc finger domainfactors may control TLR-mediated DC maturation.
Similar to TLRs, stimulation through the TNFR super- and the entire TRAF domain. TRAF6-deficient (TRAF6/)
mice appeared normal at birth, but became progres-family member CD40 leads to DC maturation and cyto-
kine production. Recent studies have shown that CD40- sively runted, and typically died by 3 weeks of age.
TRAF6/ mice exhibited severe osteopetrosis, thymicinduced cytokine production by DCs also depends on
the activation of NF-B subunits p50 and cRel (Ouaaz atrophy, lymph node deficiency, and splenomegaly.
Spleens from TRAF6/ mice were found to be markedlyet al., 2002), suggesting that NF-B activation may occur
at the point of convergence for signaling pathways ema- disorganized, with a complete lack of normal T and B
cell areas. Small clumps of lymphocytes were foundnating from both CD40 and the TLR family, and resulting
in inflammatory cytokine production by DCs. However, scattered throughout splenic sections, but distinct peri-
arteriolar or lymphoid collections were absent (data notthe existence of such a point of convergence for these
distinct signaling pathways, as well as the specific iden- shown). These observations are consistent with those
of previously reported TRAF6-deficient mice lackingtity of signaling mediators and transcription factors that
regulate CD40-mediated DC maturation, remains un- exon 3 or exon 4 (Lomaga et al., 1999; Naito et al., 1999).
certain.
TRAF6 is a member of the TRAF (TNF receptor-associ- Phenotypic Maturation and Cytokine Production Are
Impaired in TRAF6-Deficient DCsated factor) family of proteins, which have been charac-
terized as adaptor molecules that mediate signals in- To determine the function of TRAF6 in DCs, we first
examined phenotypic maturation of cultured DCs in vitroduced by the TNFR superfamily (Arch et al., 1998; Chung
et al., 2002). TRAF6 recognizes and binds to a peptide in response to various TLR ligands and CD40L. Since
TRAF6 deficiency caused severe osteopetrosis, re-motif (PXEXXAr/Ac) in the cytoplasmic portion of CD40
and TRANCE receptor (TRANCE-R, also known as sulting in occlusion of the bone marrow cavity, we gener-
ated DCs from spleen cells of TRAF6/ mice and age-RANK) (Ye et al., 2002). Upon stimulation, interaction of
TRAF6 with CD40 or TRANCE-R activates NF-B tran- matched control littermates. DCs were stimulated with
LPS (for TLR4), poly (I:C) (for TLR3), CpG-DNA (for TLR9),scription factors and mitogen-activated protein (MAP)
kinases (Ishida et al., 1996; Kobayashi et al., 2001; Lo- peptidoglycan (PGN) (for TLR2), lipoteichoic acid (LTA)
(for TLR4), or CD40L for 24 hr, followed by flow cytomet-maga et al., 1999; Wong et al., 1998). A unique feature
of TRAF6 is that, unlike other TRAFs, it also participates ric assessment of surface expression of MHC class II
(I-Ab) and B7.2 (CD86). There was no difference in thein IL-1R/TLR family signaling (Cao et al., 1996). In this
pathway, TLR-MyD88 association activates IRAK, which surface expression levels of MHC class II or B7.2 between
untreated immature TRAF6/ DCs and control DCs.in turn leads to TRAF6-mediated activation of the NF-
B and MAPK cascades (Medzhitov et al., 1998; Muzio Consistent with previous reports (Banchereau et al.,
2000; Kaisho and Akira, 2001), MHC class II and B7.2et al., 1998). It seems, therefore, that TRAF6 functions
at the central point where signals induced by the TLR were strongly upregulated on wild-type DCs in response
to all TLR stimuli tested and CD40L (Figure 1A). In con-and TNFR families converge.
To clarify the biological significance of TRAF6 in DCs, trast, upregulation of surface expression of MHC class
II was significantly impaired in TRAF6/ DCs in re-we have utilized TRAF6-deficient mice and bone marrow
(BM) chimeras reconstituted with TRAF6-deficient fetal sponse to all stimuli tested (Figure 1A). Similarly, TLR
ligands failed to upregulate B7.2 on TRAF6/ DCs.liver cells. We show here that the absence of TRAF6
causes impaired DC maturation in response to microbial CD40L, however, induced upregulation of B7.2 on
between PBS-injected (filled histogram) and anti-CD40-injected (open histogram) mice.
(C) Cytokine production is impaired in TRAF6-deficient DCs. DCs were generated from spleens of TRAF6/ (filled column) or control littermates
(open column). IL-12 p40 and IL-6 levels were measured by ELISA. Means  SD of triplicate samples of one representative experiment out
of three independent experiments are shown.
(D) DCs were stimulated with LPS for the indicated times. In the left panel, NF-B activation was determined by Western analysis. In the right
panel, the expression of IFN-inducible genes (GARG16, IP10, and IRG1) was examined by real-time PCR analyses.
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Figure 2. TRAF6 Is Required for Optimal
Stimulation of T Cells by DCs
(A–C) TRAF6/ DCs are defective in their ca-
pacity to prime allogeneic T cells in vivo. DCs
were generated from spleens of TRAF6/
mice or control littermates, and stimulated
with LPS or left untreated. DCs were injected
into Balb/c mice; then 7 days later, splenic
T cells were isolated, labeled with CFSE, and
restimulated for 3 days with T cell-depleted
129/Sv x C57BL/6 splenocytes. (A) CFSE pro-
files of restimulated CD3 T cells from DC-
primed Balb/c mice are shown. The data are
representative of three independent experi-
ments. (B) Mitotic events of restimulated
T cells in (A) were determined as described
in the Experimental Procedures. (C) IFN-
production from restimulated T cells in (A)
was measured by ELISA.
(D) TRAF6/ BMDCs are defective in their
capacity to prime antigen-specific T cells in
vivo. OTII CD4 T cells were adoptively trans-
ferred into recipient mice, followed 24 hr later
by immunization with either PBS (open col-
umn), wild-type untreated (filled column), or
LPS-treated (checked column) BMDCs, or
TRAF6/ untreated (filled column) or LPS-
treated (checked column) BMDCs. The number
of donor T cells recovered 4 days postimmunization relative to total recipient splenocytes and normalized to the PBS immunization condition
is depicted. The data expressed is representative of the mean recovery obtained from duplicate mice.
TRAF6/ DCs, although the expression levels were DCs, some biochemical responses to microbial prod-
ucts appear to remain intact. For example, LPS stimula-slightly reduced compared to those of control DCs. Simi-
lar results were obtained using cultured bone marrow tion of TRAF6/ DCs resulted in activation of NF-B,
though somewhat delayed and less robust in compari-DCs derived from TRAF6/ fetal liver cell-reconstituted
chimeric mice (data not shown). These results indicate son to wild-type DCs (Figure 1D). In addition, LPS-
induced expression of IFN-dependent genes bythat optimal DC maturation in vitro by TLR- or CD40-
mediated stimulation is dependent on TRAF6. The TRAF6/ DCs is comparable to that of wild-type DCs
(Figure 1D).TRAF6-independent mechanism by which CD40L in-
duces expression of B7.2 remains unknown. It is possi-
ble that, in this context, the utilization by CD40 of addi- LPS-Induced T Cell Stimulatory Capacity
of TRAF6-Deficient DCs Is Impairedtional TRAF proteins not used by the TLR family (e.g.,
TRAF2) may compensate for the lack of TRAF6. To determine the functional properties of TRAF6/DCs,
we examined their capacity to induce T cell stimulation.We next examined in vivo phenotypic maturation of
splenic DCs induced by LPS or CD40. Splenic CD11chigh First, the influence of LPS-treated or untreated DCs on
in vivo allogeneic T cell priming was examined. Balb/ccells from PBS-injected TRAF6/ mice and normal lit-
termates showed moderate but similar expression levels mice were injected with cultured DCs derived from
TRAF6/or wild-type spleen (129/Sv x C57BL/6). Sevenof MHC class II and B7.2 (Figure 1B). The expression
levels of these surface molecules were strongly in- days later, splenic T cells from immunized mice were
isolated and restimulated with T cell-depleted spleno-creased in control mice by injection of LPS or anti-CD40
antibody. However, neither LPS nor CD40 induced cytes from 129/Sv x C57BL/6 mice. The proliferative
response to allogeneic antigens of T cells from miceupregulation of surface molecules in TRAF6/ mice.
Together with the in vitro-cultured DC experiments, primed with LPS-treated wild-type DCs was significantly
enhanced compared to T cells from mice injected withthese results imply that TRAF6 is required for DC matu-
ration in response to microbial components, such as untreated wild-type DCs (Figures 2A and 2B). In con-
trast, the proliferative response of T cells from miceLPS or the TNF superfamily member CD40L, both in
vitro and in vivo. primed with TRAF6/ DCs was not augmented by LPS
treatment, suggesting that TRAF6 is required for an LPS-We also measured IL-6 and IL-12 levels in the culture
of DCs activated by TLR ligands or CD40L. Although induced increase in allostimulatory capacity of DCs.
We further investigated the allostimulatory capacityboth IL-6 and IL-12 levels were dramatically induced in
the culture supernatant of wild-type DCs by all stimuli, of TRAF6/ DCs by assessing the production of Th1
(IFN-) and Th2 (IL-4 and IL-10) cytokines by T cells incytokine production by TRAF6/ DCs was significantly
impaired (Figure 1C). These results indicate that CD40L an MLR. IFN-production by restimulated T cells primed
in vivo with LPS-treated wild-type DCs was remarkablyand microbial components stimulate cytokine produc-
tion from DCs in a TRAF6-dependent manner. increased compared to that of T cells primed with un-
treated wild-type DCs (Figure 2C). In contrast, restimu-Despite defects in the maturation process of TRAF6/
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Figure 3. Splenic DC Development Is Se-
verely Impaired in the TRAF6/ Mouse
Splenocytes were stained for CD11c, CD4,
and CD8. Histograms of CD11c expression
in total splenocytes are shown in the far left
panels. Percentages of gated CD11chigh popu-
lations are shown. Profiles of CD11c versus
CD4 and CD11c versus CD8 in total spleno-
cytes are shown in the middle left and middle
right panels, respectively. Percentages of the
encircled CD4 DC and CD8 DC popula-
tions are shown. Profiles of CD4 versus CD8
in CD11chigh DC populations are shown in the
far right panels. The data are representative
of at least three mice for each condition.
lated T cells primed with either LPS-treated or untreated in regulation of DC development (Ouaaz et al., 2002; Wu
TRAF6/ DCs exhibited a low amount of IFN- produc- et al., 1998). Therefore, we examined whether TRAF6
tion, which was consistent with a defective capacity for regulates splenic DC development in vivo. As most
induction of allogeneic T cell proliferation. Thus, the TRAF6/ mice die by 2.5–3 weeks of age, spleen cells
LPS-induced Th1-like response evoked by TRAF6/ from 2-week-old TRAF6/ mice and age-matched lit-
DCs was largely abolished. However, IL-4 and IL-10 termates were used in these experiments. We have also
were below detectable levels in all conditions (data not included 10-week-old C57BL/6 spleens as a control for
shown), suggesting that the defect in IFN- production normal, adult mice.
by restimulated T cells primed with LPS-treated Ten-week-old C57BL/6 mice exhibited a distinct pop-
TRAF6/ DCs was not due to a skewing toward a Th2 ulation of CD11chigh cells (1.59  0.34%) (Figure 3 and
response. Table 1). Analysis of different DC subsets determined
We have also examined the function of TRAF6/ DCs by surface expression of CD4 and CD8 on CD11chigh
in a T cell response to a model peptide antigen. For cells showed the CD48 population (CD4 DCs) to
this, chicken ovalbumin (OVA)-specific OTII CD4 T cells be the predominant DC subset (41.3  2.5%) in control
were adoptively transferred into C57BL/6 mice, which mice (Figure 3, right panel), a finding consistent with
were then immunized with OVA-loaded, LPS-treated, or previous reports (Shortman and Liu, 2002). Although
untreated DCs. Four days postimmunization, recipient 2-week-old wild-type mice (129/Sv x C57BL/6) showed
splenocytes and peripheral lymph node cells were as- a lower frequency of CD11chigh cells (0.87  0.19%) than
sayed for the presence of donor OTII T cells. While very 10-week-old control mice, a distinct CD11chigh popula-
few OTII donor T cells were recovered from unimmunized tion was still evident. However, unlike 10-week-old mice,
control mice, the number increased by roughly 4-fold in all three subsets of DCs were present in roughly equal
mice immunized with untreated wild-type DCs and
numbers (Figure 3 and Table 1). The apparent increase
nearly 40-fold in mice immunized with LPS-treated wild-
in the percentage of CD4 DCs with age does not seemtype DCs (Figure 2D). In contrast, the number of donor
to result from differences in genetic backgrounds as 4-T cells recovered from mice immunized with untreated
to 10-week-old 129/Sv x C57BL/6 control mice show aTRAF6/DCs was roughly equal to that of unimmunized
DC subset pattern similar to 10-week-old C57BL/6 con-mice, and the number found in mice injected with LPS-
trol mice (data not shown).treated TRAF6/ DCs was only roughly equivalent to
Surprisingly, the frequency of CD11chigh DCs inthe number found in mice immunized with untreated
2-week-old TRAF6/ mice was strikingly lower (0.2%)wild-type DCs. Additionally, CFSE dye dilution indicated
than that of control, age-matched littermates, such thatthat, whereas the vast majority of donor T cells recov-
a distinct CD11chigh population was indistinguishableered from mice injected with LPS-treated wild-type DCs
(Figure 3 and Table 1). Despite similar total splenic cellu-had divided repeatedly, about half of those recovered
larity, TRAF6/ mice exhibited a 5.6-fold reduction infrom mice immunized with LPS-treated TRAF6/ DCs
the total number of splenic DCs compared to age-failed to divide at all (data not shown). These data further
matched littermates (Table 1). Furthermore, the CD4suggest an inability of DCs to induce or potentiate either
DC population was almost completely absent inor both proliferation and survival of antigen-specific
TRAF6/ mice compared to age-matched littermatesT cells in the absence of TRAF6-mediated signaling.
(31-fold reduction). Though the CD8 and double-neg-Taken together, these results showed that, similar to
ative (DN) populations were clearly identifiable in thean allogeneic response, TRAF6/ DCs fail to induce
small number of CD11chigh cells present in TRAF6/peptide antigen-specific T cell responses.
mice, their numbers were significantly reduced (5.5-fold
reduction of CD8 DCs and 3.3-fold reduction of DNSplenic DC Development Is Severely Impaired
DCs). The plasmacytoid DC population (CD11clo,in the TRAF6/ Mouse
CD45R, CD19, MHC class IIlo) was observed with theTRAF6 is known to activate NF-B family transcription
factors, some members of which have been implicated same frequency in the spleens of both TRAF6/ and
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Table 1. Cellularity of Splenic DCs
DC Numbers per Organ  103
Total Cells per
Mouse Organ  106 Total CD4 DC (%)a CD8 DCs (%)a DN DCs (%)a
C57BL/6 10-week-old 61.3  7.0 957  93 397  57 (41.3  2.5) 257  25 (27.0 3.5) 280  38 (29.2  1.5)
TRAF6 WT 2-week-old 41.7  4.5 344  56 106  34 (30.3  5.3) 94  21 (28.3  11) 132  46 (37.4  7.6)
TRAF6 KO 2-week-old 39.6  3.4 61  25 3.4  1.9 (5.5  2.1) 17  5.5 (32.6  18) 40  25 (61.3  16)
BM Chimera TRAF6 WT 78.4  17.6 1450  319 935  192 (64.8  4.7) 167  54 (11.3 1.7) 312  99 (21.4  4.1)
BM Chimera TRAF6 KO 46.6  12.7 423  121 38  20 (8.8  3.0) 200  53 (47.9 6.5) 172  57 (40.3  3.3)
RelB WT 7-week-old 56.7  5.0 1030  162 512  67 (49.9  1.3) 228  70 (21.8 3.3) 232  36 (22.6  1.3)
RelB KO 7-week-old 157.8  11.1 1000  324 131  36 (13.2  0.9) 411  136 (40.9 0.4) 426  138 (42.4  0.7)
Data represent means  SD. At least three mice were used for each condition.
a Percentage of each subset in total DCs. Abbreviations: WT, wild-type; KO, knockout.
control mice (data not shown), indicating selective ef- between the CD4 and DN subsets (Wu et al., 1998). To
fects of TRAF6 deficiency. examine whether RelB, like TRAF6, regulates CD4 DC
development, we analyzed splenic DC subsets in RelB-
TRAF6 Is Essential for the Development of CD4, deficient mice. The frequency of CD11chigh DCs was re-
but Not CD8, DCs markably reduced in RelB-deficient mice compared to
To determine whether the defect in splenic DC develop- age-matched control littermates (more than a 2-fold re-
ment in TRAF6/ mice was a direct effect of TRAF6 duction) (Figure 5 and Table 1). However, since RelB-
deficiency in the hematopoietic compartment, as op- deficient mice exhibit splenomegaly (nearly a 3-fold in-
posed to a secondary effect of growth retardation or crease in total splenocytes), the total number of splenic
the lack of a bone marrow cavity, we generated BM DCs in RelB-deficient mice was found to be comparable
chimeras reconstituted with fetal liver cells from to that of control littermates (Table 1). In comparison to
TRAF6/ or wild-type littermate fetuses (designated control mice the frequency and absolute number of
TRAF6/ BM chimera and wild-type BM chimera, re- CD4 DCs in RelB-deficient mice were remarkably re-
spectively). Seven to twelve weeks after adoptive trans- duced (approximately a 4-fold reduction in each case)
fer of fetal liver cells, splenic DC populations were exam- (Figure 5A and Table 1). Roughly twice as many CD8
ined as described above. A distinct population of DCs and DN DCs were found in RelB-deficient spleens
CD11chigh cells (1.95  0.16%, 	99% of CD45.2 cells) as compared to control spleens (Figure 5A and Table
was observed in the spleens of BM chimeric mice recon- 1). Thus, RelB seems to be required for CD4 CD8
stituted with wild-type fetal liver cells (Figure 4 and Table DC development in vivo.
1). Analysis of DC subsets in wild-type BM chimeras RelB forms potent transcriptional activators by asso-
revealed that the CD4 DC subset was predominant ciating with p50 or p52 (Ghosh and Karin, 2002), but
(64.8  4.7%). In contrast, TRAF6/ BM chimeras ex- the lack of p50 alone has been shown not to affect
hibited a markedly reduced frequency and total number development of splenic DCs (Ouaaz et al., 2002). Thus,
of CD11chigh cells (0.92  0.21%, 3.4-fold reduction), in we examined splenic DC subsets in p52-deficient mice
conjunction with a near complete absence of CD4 DCs and found that they exhibit total CD11chigh and CD4 DC
(25-fold reduction). At the same time, TRAF6/ BM chi- populations similar in number and proportion to age-
meric spleens contained about half the number of DN matched control littermates (Figure 5A).
DCs and a comparable number of CD8 DCs in com-
parison to wild-type BM chimeric spleens (Table 1).
Expression of TRAF6 and RelB mRNA in SplenicTaken together, these results indicate that TRAF6 regu-
DC Subsetslates splenic CD4 DC development in vivo.
To determine whether the differential effects of TRAF6
and RelB deficiency on splenic DC subsets correlateDefect in CD4 DC Development
with their expression levels, we sorted each subset fromin RelB-Deficient Mouse
wild-type spleens and prepared cDNA for mRNA analy-The NF-B subunit RelB has been implicated in splenic
CD11c CD8 DC development but without distinction sis by real-time PCR. The normalized TRAF6 mRNA ex-
Figure 4. TRAF6 Is Essential for the Develop-
ment of CD4, but Not CD8, DCs
Splenocytes from BM chimeric mice reconsti-
tuted with either TRAF6/ or wild-type fetal
liver cells were analyzed as described in Fig-
ure 3. Profiles of CD11c expression (far left
panels), CD11c versus CD4 (middle left pan-
els), and CD11c versus CD8 (middle right
panels) in total splenocytes, and profiles of
CD4 versus CD8 in CD11chigh DC popula-
tions (far right panels) are shown. The data
are representative of at least five mice for
each condition.
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Figure 5. RelB Is Required for CD4 DC De-
velopment; TRAF6 and RelB mRNA Expres-
sion in DC Subsets
(A) Profiles of splenic DC subsets in RelB KO
mice, p52 KO mice, and age-matched control
mice are shown. The data are representative
of at least four mice for each condition.
(B) CD4DCs, CD8 DCs, and double-nega-
tive (DN) DCs from wild-type spleens were
sorted using a MoFlo cell sorter. RelB and
TRAF6 mRNA expression levels in each sub-
set were assessed by real-time PCR. TRAF6
and RelB expression levels were normalized
to internal HPRT expression. The data indi-
cate means SD of triplicate samples of one
representative experiment out of three inde-
pendent experiments (*, p  0.01; **, p 
0.05).
pression level was approximately 1.5-fold greater in the definitions should not be accepted as absolute, they
reflect current views in the field of DC biology (Banche-CD4DC subset than the CD8 and DN subsets (Figure
5B). Also, the CD4 DC subset expressed roughly 3- or reau et al., 2000; Banchereau and Steinman, 1998;
Shortman and Liu, 2002). With that in mind, the data we6-fold more RelB mRNA than the CD8 or DN subsets,
respectively (Figure 5B). These results are consistent have presented in this study regarding the role of TRAF6
in DC function should be addressed in the context ofwith the observation that defects in TRAF6 or RelB have
the most profound effects on the CD4 DCs. the ability of distinct immune receptor families, TLR and
TNFR, to induce identical cellular responses (Figure 6).
Discussion
DC Maturation
Microbial products have clearly been shown to stimulateTRAF6 and DC Maturation/Activation
The innate immune system triggers a host defense re- DCs via distinct TLRs. For example, LPS- and CpG-
DNA-induced DC maturation is abolished in TLR4- andsponse against invading microorganisms via signaling
by DCs through TLRs (Janeway and Medzhitov, 2002). TLR9-deficient mice, respectively (Hemmi et al., 2000;
Kaisho et al., 2001; Kaisho and Akira, 2001).Signals from TNFR superfamily members (e.g., CD40,
TRANCE-R) also contribute to regulation of multiple However, despite the establishment of specific li-
gand-receptor pairs, it has remained unclear how suchfunctions of DCs (Banchereau and Steinman, 1998; Jo-
sien et al., 2000; Miga et al., 2001; Wong et al., 1997). diverse microbial products and their cognate receptors
could lead to a common DC maturation process. TheAlthough distinctions between DC maturation and DC
activation remain unclear, previous reports have sug- simplest hypothesis suggests that a common intracellu-
lar signaling molecule used by all members of the TLRgested that these processes are genetically distinguish-
able with respect to stimulation via microbial products family, such as MyD88, mediates DC maturation. How-
ever, studies of MyD88/ DCs have shown that whileor CD40L (Kaisho et al., 2001; Ouaaz et al., 2002). Our
findings are of particular importance to understanding MyD88 is required for DC maturation by many of the TLR
family members (e.g., TLR9), LPS-stimulated MyD88/both DC “maturation” and “activation,” which we define
here, respectively, as (1) the upregulation of surface DCs express normal levels of MHCII and costimulatory
molecules, and efficiently induce T cell proliferationexpression of MHC and other costimulatory molecules
capable of enhancing proliferation of naive T cells, and (Kaisho et al., 2001; Schnare et al., 2001). The results
thus imply that, for DC maturation, there must be a(2) the production of inflammatory cytokines (e.g., IL-
12) which regulate T cell differentiation. Though these MyD88-independent pathway utilized by some mem-
Immunity
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Moreover, our data argue that TRAF6 is also responsi-
ble for DC maturation induced by the TNF superfamily
member CD40L. Together, these results indicate that
both the TLR family members and CD40, a critical DC-
regulatory TNFR superfamily member, utilize a common
signaling pathway controlled by TRAF6 for DC matura-
tion. Although TRAF6 activates several kinases (e.g.,
MAPK, IKK, PI3K, AKT) and transcription factors (AP-1,
NF-B), the specific requirement for each during either
TLR- or CD40L-induced DC maturation remains unclear
and will be the focus of future studies. Finally, it is impor-
tant to note that there is likely not an intrinsic require-
ment for functional TRAF6 during DC maturation, as, for
example, serial replating of TRAF6/ DCs in culture
plates induces maturation similar to that of wild-type
DCs (data not shown).
DC Activation
One of the hallmarks of DC activation is the production of
inflammatory cytokines, such as IL-12, upon stimulation
with microbial products or CD40L. Several important
observations have been reported regarding potential
convergence of the signaling cascades induced by the
TLR family and CD40 during induction of DC activation
(Kaisho et al., 2001; Ouaaz et al., 2002). First, studies
using MyD88/ DCs clearly showed that MyD88 is es-
Figure 6. A Model for TRAF6-Mediated Signals which Regulate DC
sential for IL-12 production by DCs in response to allFunctions
TLR ligands tested, including LPS. Since CD40 does notSignaling pathways mediated by TRAF6 regulate DC maturation and
utilize MyD88 as a signaling adaptor (Figure 6), CD40-activation, as well as DC development. Upon recognition of PAMPs,
induced cytokine production by MyD88/ DCs is unaf-TLRs recruit MyD88, which induces interaction between MyD88 and
IRAK, allowing IRAK to form a complex with TRAF6. In addition, a fected. Second, NF-B transcription factor subunits p50
pathway(s), which may involve additional adaptor(s) (designated as and cRel are critical to DC activation as demonstrated
“X”), is engaged by TLR4 in response to LPS, resulting in DC matura- by the failure p50/cRel/ DCs to produce cytokines
tion in a MyD88-independent manner. The TNF superfamily member
in response to LPS or CD40L (Ouaaz et al., 2002).CD40 associates directly with TRAF6. Signals from various TLRs
The data we present in this study show that TRAF6and CD40 merge at TRAF6 and lead to subsequent activation of
is required for DC cytokine production induced by eitherAP-1 and NF-B. Together, these downstream signals and transcrip-
tion factors regulate DC maturation and cytokine production. An the TLR family or CD40. Our findings together with those
unidentified ligand-receptor pair(s) (designated “?”) regulates of other groups suggest that TRAF6 is positioned at the
splenic DC development via a TRAF6-mediated process. point of convergence of NF-B-dependent DC-activat-
ing signals emanating from CD40 or the TLR family.
bers of the TLR family, including TLR4. Another adaptor
protein in the TLR signaling pathway, TIRAP (also known TRAF6 and Splenic DC Subsets
In this study we also showed that TRAF6 is requiredas Mal), has been identified and shown to function
downstream of TLR4, and thus may be partially respon- for normal splenic DC development. In particular, CD4
DCs, the major splenic DC subset, were found to besible for the MyD88-independent response (Fitzgerald
et al., 2001; Horng et al., 2001). However, LPS can still almost completely absent in TRAF6/ mice and
TRAF6/ BM chimeras. These results indicate thatinduce maturation in DCs from MyD88 and TIRAP double
knockout mice, indicating that TIRAP is likely not critical TRAF6 is required for proper development of CD4 DCs,
a subset that appears to uniquely regulate T cell functionto LPS-induced MyD88-independent DC maturation
(Yamamoto et al., 2002). Therefore, to date there has among splenic DCs (Legge et al., 2002; Moser and Mur-
phy, 2000; Shortman and Liu, 2002). However, it remainsexisted little data supporting a model for convergence
of DC maturation signals emanating from the TLR family unclear whether the observed absence of the CD4 DC
subset is due to an inability of CD4 DC precursor cellsgamut.
Our data shows that TRAF6, an adaptor downstream to further differentiate, a selective survival defect in the
CD4 DC subset or a combination of both. Thoughof MyD88 (and possibly TIRAP) (Figure 6), is required for
DC maturation induced by TLR family members which TRAF6 appears to be required to some extent for main-
tenance of the DN DC subset, the relative significanceutilize either MyD88-dependent (e.g., TLR9) or MyD88-
dependent and -independent (e.g., TLR4) mechanisms. may be less than for the CD4 DC subset, while the
reduced numbers of CD8 DCs observed in 2-week-Therefore, these results provide evidence that there is
an intracellular molecule representing a point of conver- old TRAF6/ mice is likely an indirect effect of TRAF6
deficiency.gence for all signaling cascades activated by various
microbial products and their cognate TLRs during DC Since NF-B is one of the major downstream targets
of TRAF6 signaling, and RelB has been previously impli-maturation.
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fragment of the 3
 intron at the 3
 region, respectively. A loxP sitecated in CD8 DC development (Wu et al., 1998), it
was placed (in the same orientation) between the LH and the neo,was important to reexamine the splenic DC subsets in
between the neo and the exon, and between the STOP and IRES-RelB-deficient mice to see whether the defect is re-
EYFP fragments. The mutation in ES cells was identified by PCR
stricted to the CD4 subset. Our results indicated that with primers, T6-Screen1 (5
-GCTGGGAACAGTTTAACTTATGC-3
)
RelB-deficient mice show a selective defect in the CD4 and T6-Screen3 (5
-GGCTCTATGGCTTCTGAGGC-3
), and by
Southern analysis using a 3
-external probe. The exon in the knockinDC (Figure 5). Our data is, however, in contrast to the
ES clones was deleted by pMC-Cre transfection in vitro. The deletionprevious report which showed a near complete absence
was identified by PCR with primers, IRES/Cre-Screen1 (5
-of all CD8 DCs in RelB-deficient mice (Wu et al., 1998).
CTTCGGCCAGTAACGTTAGGG-3
) and T6LH/Cre-Screen1 (5
-It should be noted, however, that the RelB-deficient
GTAAAGACAGAGAGTAGGTAGCCTG-3
), and by Southern analy-
mouse used in the previous study was generated by the sis. The mutant ES clones were injected into C57BL/6 blastocysts.
accidental insertion of a transgene (Burkly et al., 1995; RelB-deficient mice, p52-deficient mice, and OTII TCR transgenic
mice have been described (Barnden et al., 1998; Caamano et al.,Wu et al., 1998), while the RelB-deficient mouse used
1998; Weih et al., 1995).in this study was made by homologous recombination
For generation of bone marrow chimeras, adoptive transfer of(Weih et al., 1995). The different methods employed in
TRAF6/ fetal liver cells was performed as described (Zheng et al.,generating RelB deficiencies may account for the incon-
2001).
sistent phenotypes observed.
Together these data suggest that TRAF6 and RelB Reagents and Antibodies
operate in the same signaling cascade, with RelB likely LPS, PGN, and LTA were from Sigma. Poly (I:C) was from Amersham
Pharmacia Biotech. Phosphorothioate-stabilized CpG-DNA wasdownstream of TRAF6, and both are required for regula-
synthesized as described (Hemmi et al., 2000). Antibodies were fromtion of CD4 DC development. However, the extent of
BD Pharmingen (CD3; 145-2C11, CD4; RM4-5, CD8; 53-6.7, CD11b;the defect in CD4 DC development in TRAF6/ mice
M1/70, CD11c; HL3, CD16/32; 2.4G2, CD40; HM40-3, CD45.1; A20,is more severe than that found in RelB-deficient mice.
CD45.2; 104, CD86; GL1, I-Ab; AF6-120.1, I-Ad; 39-10-8, Thy1.2;
Considering the diversity of TRAF6 downstream targets 53-2.1; IFN; R4-6A2, XMG1.2, IL-4; BVD6-24G2, 11B11, IL-6; MP5-
(Figure 6), it is also possible that TRAF6 regulates CD4 20F3, MP5-32C11, IL-10; JES5-16E3, JES5-2A5). Biotinylated anti-
body staining was followed by streptavidin-PerCP Cy5.5 (BD Phar-DC development in a RelB-independent manner. To pro-
mingen).vide insights into potential mechanisms regulating CD4
DC development through TRAF6 and RelB signals, we
In Vitro DC Cultureexamined mRNA expression levels of TRAF6 and RelB
DCs were generated from spleens of 2-week-old TRAF6/ mice orin each subset. Interestingly, we showed that TRAF6
BM cells from chimeras as described (Inaba et al., 1992) with some
and RelB were expressed most abundantly, though not modifications for spleen-derived DCs. In brief, erythrocytes, T cells,
exclusively, in CD4 DCs. Whether the level of TRAF6 B cells, and MHC II-positive cells were depleted, and 6  106 cells
in 1 ml of medium (RPMI-1640, 5% FCS, 10 mM HEPES, 5  105or RelB expression is an important factor for CD4 DC
M 2-mercaptoethanol, penicillin [100 IU/ml]/streptomycin [100 g/development requires further study. However, it has
ml]) supplemented with 3.3% J558L-conditioned medium were cul-been shown that quantitative differences in expression
tured. On day 8, loosely adherent cells were harvested for experi-of a signaling molecule can affect the development of
ments.
specific cell types. For example, high expression of c-Src For phenotypic analysis of DC maturation, day 7 DCs were stimu-
in myeloid precursors affects osteoclast, but not DC or lated with LPS (10 ng/ml), poly (I:C) (20 g/ml), CpG-DNA (10 M),
PGN (10 g/ml), LTA (1 g/ml), or 1:200 dilutions of CD40L-con-macrophage, development (Roodman, 1999). In either
taining supernatant (Wong et al., 1997) for 24 hr, harvested on daycase, further studies are required to determine whether
8, and analyzed with anti-CD11c, anti-CD86, and anti-I-Ab Abs. ForTRAF6- and RelB-mediated pathways regulating the
cytokine assays, cells were treated with stimuli for 48 hr, and super-fate of the CD4 DC population are linked.
natants harvested on day 8. IL-12 p40 levels were measured using
mAb C17.8 and biotinylated mAb C15.6, and IL-6 levels using mAb
MP5-20F3 and biotinylated mAb MP5-32C11, as described (SpeirsConclusion
et al., 2002). For biochemical studies, day 7 DCs were harvested,This study demonstrates a critical role for TRAF6 in both
and CD11c CD45.1 DCs sorted. Purified DCs were cultured at
DC maturation and activation in response to microbial 2  106 cells/500 l in serum-free RPMI at 37C for 3 hr. DCs were
products and CD40L, and therefore provides evidence stimulated with 100 ng/ml of LPS for the indicated times and sub-
that signals generated by the IL-1R/TLR family and the jected to Western and real-time PCR analyses.
TNFR superfamily member CD40L converge. In addition,
In Vivo DC Analysiswe have provided evidence that TRAF6 is important for
For induction of DC maturation by LPS in vivo, 2-week-old TRAF6/the development of DC subsets. Hence, these results
mice and control littermates were injected i.p. with LPS (100 ng/gimply that extracellular factors involved in DC matura-
body weight) or PBS, and DCs assayed 6 hr later. For CD40-induced
tion/activation might also be important for DC subset DC maturation, mice were injected i.p. with anti-CD40 Ab (FGK115;
development and maintenance. 50 g/mouse) or PBS, and DCs examined 27 hr later. Single-cell
suspensions were prepared from spleen and analyzed by flow cy-
tometry.Experimental Procedures
Mice Adoptive Transfer of Allogeneic DCs
DCs generated by in vitro culture of spleen cells, as described above,TRAF6 KO mice were generated by homologous recombination in
ES cells using the Cre/loxP system. A 15 kb DNA fragment containing were stimulated with LPS or untreated. Cells were washed and
injected (0.5  106 cells) i.v. into Balb/c mice. After 7 days, splenicexon 7 of TRAF6 was isolated from a genomic DNA library. A 2.0
kb fragment of the exon and flanking introns was ligated with an T cells from naive or DC-primed Balb/c mice (haplotype d) were
enriched, labeled with CFSE (Molecular Probes Inc., Eugene, OR)hsv-tk cassette, a 5.5 kb long homologous (LH) fragment of the 5

intron, a neo cassette in the 5
 region, a STOP cassette (Invitrogen), as described (Wells et al., 1997), and used as responders. 2  105
total cells were placed in 96-well plates, and varying numbers ofan IRES-EYFP cassette (Clontech), and a 1.5 kb short homologous
Immunity
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-irradiated (2000 rads) T cell-depleted splenocytes from TRAF6 Burkly, L., Hession, C., Ogata, L., Reilly, C., Marconi, L.A., Olson,
D., Tizard, R., Cate, R., and Lo, D. (1995). Expression of relB isheterozygous or wild-type mice were added as stimulator cells (hap-
lotype b). After 72 hr, cells were harvested, stained with anti-CD3 required for the development of thymic medulla and dendritic cells.
Nature 373, 531–536.antibody, and analyzed by flow cytometry. Mitotic index was deter-
mined as described (Wells et al., 1997). IFN-, IL-4, and IL-10 were Caamano, J.H., Rizzo, C.A., Durham, S.K., Barton, D.S., Raventos-
measured by ELISA. Suarez, C., Snapper, C.M., and Bravo, R. (1998). Nuclear factor (NF)-
B2 (p100/p52) is required for normal splenic microarchitecture and
Adoptive Transfer of Antigen-Loaded DCs B cell-mediated immune responses. J. Exp. Med. 187, 185–196.
Bone marrow from chimeric mice was cultured for 8 days with GM-
Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D.V.CSF. From days 4–8 medium was supplemented with 100 g/ml of
(1996). TRAF6 is a signal transducer for interleukin-1. Nature 383,whole chicken OVA protein (Worthington Biochemical Corporation).
443–446.Cells were replated on days 6 and 7, and medium left untreated or
Chung, J.Y., Park, Y.C., Ye, H., and Wu, H. (2002). All TRAFs aretreated with 10 ng/ml LPS from days 7 to 8. 1.5  105 BMDCs were
not created equal: common and distinct molecular mechanisms ofresuspended in PBS and injected into two CD45.1 congenic male
TRAF-mediated signal transduction. J. Cell Sci. 115, 679–688.recipient mice. Additional recipient mice were injected with PBS
alone. Twenty-four hours prior, all CD45.1 recipient mice had been Fitzgerald, K.A., Palsson-McDermott, E.M., Bowie, A.G., Jefferies,
injected i.v. with 1.4  106 purified CFSE-labeled OTII CD4 T cells C.A., Mansell, A.S., Brady, G., Brint, E., Dunne, A., Gray, P., Harte,
(CD45.2). Four and a half days after immunization, spleens and M.T., et al. (2001). Mal (MyD88-adapter-like) is required for Toll-like
lymph nodes were harvested, and donor T cells identified with anti- receptor-4 signal transduction. Nature 413, 78–83.
bodies specific for CD45.2, CD4, and Thy1.2.
Ghosh, S., and Karin, M. (2002). Missing pieces in the NF-B puzzle.
Cell 109, S81–S96.Real-Time PCR
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H.,TRAF6, RelB, and IFN-inducible gene mRNA expression was as-
Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S.sessed using the primers below in combination with SyBr Green
(2000). A Toll-like receptor recognizes bacterial DNA. Nature 408,(Applied Biosystems). PCR primers: TRAF6 sense (5
-AACTGTGCT
740–745.GTGTCCATGGC-3
) and TRAF6 antisense (5
-CAGTCTCATGTG
CAACTGGG-3
) for TRAF6; RelB sense (5
-AGCAGCTCTGATCCA Horng, T., Barton, G.M., and Medzhitov, R. (2001). TIRAP: an adapter
CATGG-3
) and RelB antisense (5
-AGCACTGGCAAGTGGTGGTG- molecule in the Toll signaling pathway. Nat. Immunol. 2, 835–841.
3
) for RelB; GARG16 sense (5
-AGGCAGGACAATGTGCAAGAA-3
)
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara,
and GARG16 antisense (5
-CCATGCAAACATAGGCCATCT-3
) for
S., Muramatsu, S., and Steinman, R.M. (1992). Generation of large
GARG16; IP10 sense (5
-TCTGAATCCGGAATCTAAGACCAT-3
) and
numbers of dendritic cells from mouse bone marrow cultures sup-
IP10 antisense (5
-GGTGTGTGCGTGGCTTCA-3
) for IP10; IRG1
plemented with granulocyte/macrophage colony-stimulating factor.
sense (5
-ATTCGGAGGAGCAAGAGGATGAT-3
) and IRG1 anti-
J. Exp. Med. 176, 1693–1702.
sense (5
-GCTGGAGGTGTTGGAACTGTAGAT-3
) for IRG1; 5
-hypo-
Ishida, T., Mizushima, S., Azuma, S., Kobayashi, N., Tojo, T., Suzuki,xanthine ribosyltransferase (HPRT) (5
-GTAATGATCAGTCAACGG
K., Aizawa, S., Watanabe, T., Mosialos, G., Kieff, E., et al. (1996).GGGAC-3
) and 3
-HPRT (5
-CCAGCAAGCTTGCAACCTTAACCA-
Identification of TRAF6, a novel tumor necrosis factor receptor-3
) for HPRT. Detection of HPRT was used as an internal control.
associated factor protein that mediates signaling from an amino-The PCR program was as follows: 50C, 2 min; then 40 cycles (95C,
terminal domain of the CD40 cytoplasmic region. J. Biol. Chem. 271,1 min; 60C, 1 min). Signal detection was performed using an Applied
28745–28748.Biosystems 7700 Sequence Detector (Sequence Detector v1.7a
software). Janeway, C.A., Jr., and Medzhitov, R. (2002). Innate immune recog-
nition. Annu. Rev. Immunol. 20, 197–216.
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